Aberrant CDK4/6-driven cell-cycle reentry drives neuronal loss and defines a therapeutic target in C9orf72 ALS/FTD

iScience 2026 Open access

Read full text
Authors: Ling Lian, Hayley Robinson, Noah M. Daniels, G. Aleph Prieto, Gunnar H. D. Poplawski, Rodrigo Lopez-Gonzalez
DOI: 10.1016/j.isci.2025.114596
Cited by: 1
References: 30

Abstract

findings. These findings establish cell-cycle dysregulation as a central pathogenic mechanism in C9orf72 ALS/FTD and highlight CDK4/6 signaling as a promising therapeutic target.

Fields of Study & Subjects

Amyotrophic Lateral Sclerosis Research Nerve injury and regeneration Cancer-related Molecular Pathways

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
2
Pages
114596–114596
Publication date
2 January 2026
Language
EN